News Desk, AnyTV, New Delhi
Published by: Abhishek Dixit
Updated Fri, 04 Mar 2022 09:46 PM IST
Summary
The Drug Controller General of India (DCGI) on December 28 approved Kovovax for limited use in emergencies for adults. However, it has not yet been included in the country’s vaccination campaign.
The subject expert committee has recommended emergency use for another corona vaccine. According to the information, Serum Institute of India’s corona vaccine has been asked to approve the emergency use for adolescents in the age group of 12 to 17 years. Official sources gave this information on Friday.
The Drug Controller General of India (DCGI) on December 28 approved Kovovax for limited use in emergencies for adults. However, it has not yet been included in the country’s vaccination campaign. Prakash Kumar Singh, director of government and regulatory affairs at SII, had filed an application to the DCGI on February 21 seeking an EUA for Kovovax for children in the age group of 12 to 17 years.
According to sources, the Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Friday deliberated on the application of SII and recommended EUA to Kovovax. The recommendation will be sent to DCGI for approval. In the EUA’s application, Singh said data from two studies on nearly 2,700 children aged 12 to 17 years showed that Kovovax is very effective, immunosuppressive and safe.
A source quoted Singh as saying that this approval will be beneficial not only for our country but for the whole world and will fulfill the vision of our Prime Minister to produce in India for the world. In line with the vision of our CEO Aadar C Poonawalla, we are confident that Kovovax will play a vital role in protecting the children of our country and the world against COVID-19 and will keep our tricolor high in the world.
Expansion
The subject expert committee has recommended emergency use for another corona vaccine. According to the information, Serum Institute of India’s corona vaccine has been asked to approve the emergency use for adolescents in the age group of 12 to 17 years. Official sources gave this information on Friday.
The Drug Controller General of India (DCGI) on December 28 approved Kovovax for limited use in emergencies for adults. However, it has not yet been included in the country’s vaccination campaign. Prakash Kumar Singh, director of government and regulatory affairs at SII, had filed an application to the DCGI on February 21 seeking an EUA for Kovovax for children in the age group of 12 to 17 years.
According to sources, the Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Friday deliberated on the application of SII and recommended EUA to Kovovax. The recommendation will be sent to DCGI for approval. In the EUA’s application, Singh said data from two studies on nearly 2,700 children aged 12 to 17 years showed that Kovovax is very effective, immunosuppressive and safe.
A source quoted Singh as saying that this approval will be beneficial not only for our country but for the whole world and will fulfill the vision of our Prime Minister to produce in India for the world. In line with the vision of our CEO Aadar C Poonawalla, we are confident that Kovovax will play a vital role in protecting the children of our country and the world against COVID-19 and will keep our tricolor high in the world.